Page last updated: 2024-10-24

cefuroxime and Lupus Erythematosus, Systemic

cefuroxime has been researched along with Lupus Erythematosus, Systemic in 1 studies

Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.

Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Uz, E1
Bavbek, N1
Turgut, FH1
Kanbay, M1
Kaya, A1
Akcay, A1

Other Studies

1 other study available for cefuroxime and Lupus Erythematosus, Systemic

ArticleYear
Cefuroxime-induced lupus.
    Journal of the National Medical Association, 2007, Volume: 99, Issue:9

    Topics: Anti-Bacterial Agents; Cefuroxime; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged

2007